Back to results
US 2013/0295085 A1Published application
ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND USE IN THERAPY
AssigneeTrustees of Dartmouth College
InventorRandolph J. Noelle
Life of this patent
Estimating the term…
Abstract
Improved anti-CD154 antibodies are provided herein which have ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation and allergic disorders is disclosed herein.
Claims26
A human, chimeric or humanized antibody of the human IgGI or IgG3 isotype that is specific to human CD154 wherein the Fc region of the antibody is mutated to eliminate or substantially reduce FcR binding in a manner that renders it substantially non-thrombogenic.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.